TAD
7.12.2020 13:33:04 CET | Business Wire | Press release
Toyama Prefectural Museum of Art and Design is inviting entries for “The 13th International Poster Triennial in Toyama 2021” (IPT2021), the only poster exhibition in Japan opens to international entries, held once every three years. Due to the spread of COVID-19, and considering the overseas mail situation, we decided on November 13, 2020 to extend the deadline for entries to February 28, 2021 (Sun.).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201206005062/en/
IPT2021 is an exhibition showcasing posters chosen from throughout the world, designed to provide a review of the current state and achievements in international poster design. It is scheduled to be held from mid-July to early September 2021.
In addition to paper-format entries for Categories A and B, we have expanded the digital-data category for young designers introduced at the last IPT to create a “U30+Student Category” accepting entries from students aged 30 or older.
Details of Entry Guidelines are posted on the IPT2021 page on our Museum’s website.
Special IPT2021 webpage: https://tad-toyama.jp/en/ipt
[
Entry Categories]
*For details, please consult the Entry Guidelines.
Category A
Paper-format posters. No fixed theme. (Open to both client works and independent works. Posters created in or after May 2018.)
Category B
Paper-format posters. Independent works on the theme “INVISIBLE.”
U30+Student
[
Expanded entry from this IPT]
Open to entries from participants aged 30 or younger (born in 1990 or later), or students currently enrolled in an educational institution (students aged 30 or older can enter).
Entries submitted as digital data. Independent works on the theme “INVISIBLE.”
[
Period for submitting entries]
September 1, 2020 (Tues.) - arriving no later than February 28, 2021 (Sun.)
*Extended from original deadline of December 10, 2020 (Thurs.)
*In the event of any changes in schedule, etc. of IPT2021 due to the spread of COVID-19, we will notify you on the IPT2021 page (https://tad-toyama.jp/en/ipt ) on our Museum’s website.
About Toyama Prefectural Museum of Art and Design (TAD)
We introduce world-class collections from new perspectives, with original themes and presentation styles. We offer programs where you can make new discoveries on each visit, actively incorporating design viewpoints in response to this new era. Our goal is to be a platform connecting people to art and design.
Renowned architects and designers have contributed greatly, with Hiroshi Naito responsible for architectural design, Kazumasa Nagai for our logo, Issey Miyake for designing uniforms, and Taku Satoh designed posters announcing the opening of the Museum.
https://tad-toyama.jp/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20201206005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com
Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release
Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that
2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release
CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen
Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release
A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom